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Eﬀ ect of early intensive multifactorial therapy on 5-year 
cardiovascular outcomes in individuals with type 2 diabetes 
detected by screening (ADDITION-Europe): 
a cluster-randomised trial
Simon J Griﬃ  n, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy E H M Rutten, Annelli Sandbæk, Stephen J Sharp, Rebecca K Simmons, 
Maureen van den Donk, Nicholas J Wareham, Torsten Lauritzen
Summary 
Background Intensive treatment of multiple cardiovascular risk factors can halve mortality among people 
with established type 2 diabetes. We investigated the eﬀ ect of early multifactorial treatment after diagnosis 
by screening.  
Methods In a pragmatic, cluster-randomised, parallel-group trial done in Denmark, the Netherlands, and the UK, 
343 general practices were randomly assigned screening of registered patients aged 40–69 years without known 
diabetes followed by routine care of diabetes or screening followed by intensive treatment of multiple risk factors. The 
primary endpoint was ﬁ rst cardiovascular event, including cardiovascular mortality and morbidity, revascularisation, 
and non-traumatic amputation within 5 years. Patients and staﬀ  assessing outcomes were unaware of the practice’s 
study group assignment. Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, 
number NCT00237549.
Findings Primary endpoint data were available for 3055 (99·9%) of 3057 screen-detected patients. The mean age 
was 60·3 (SD 6·9) years and the mean duration of follow-up was 5·3 (SD 1·6) years. Improvements in cardiovascular 
risk factors (HbA1c and cholesterol concentrations and blood pressure) were slightly but signiﬁ cantly better in the 
intensive treatment group. The incidence of ﬁ rst cardiovascular event was 7·2% (13·5 per 1000 person-years) in the 
intensive treatment group and 8·5% (15·9 per 1000 person-years) in the routine care group (hazard ratio 0·83, 95% CI 
0·65–1·05), and of all-cause mortality 6·2% (11·6 per 1000 person-years) and 6·7% (12·5 per 1000 person-years; 0·91, 
0·69–1·21), respectively.
Interpretation An intervention to promote early intensive management of patients with type 2 diabetes was associated 
with a small, non-signiﬁ cant reduction in the incidence of cardiovascular events and death.
Funding National Health Service Denmark, Danish Council for Strategic Research, Danish Research Foundation for 
General Practice, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of Health, 
Danish Medical Research Council, Aarhus University Research Foundation, Wellcome Trust, UK Medical Research 
Council, UK NIHR Health Technology Assessment Programme, UK National Health Service R&D, UK National 
Institute for Health Research, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, 
Novo Nordisk, Astra, Pﬁ zer, GlaxoSmithKline, Servier, HemoCue, Merck.
Introduction
Type 2 diabetes mellitus is common, expensive to 
manage, and associated with a substantial burden of 
morbidity and mortality, particularly owing to cardio-
vascular com plications.1 Risk of cardiovascular events 
and death can be halved among patients with longstand-
ing diabetes and microalbuminuria by intensive multi-
fact orial treatment.2,3 Treatment of individual risk factors, 
such as blood pressure,4,5 cholesterol,6 and glucose,7 is 
eﬀ ective. Outcomes might be improved if this approach 
were used early in the course of the disease.8 The eﬀ ect of 
start ing multifactorial treatment from the time of 
diagnosis is unknown.
Type 2 diabetes is detectable well before it is clinically 
diagnosed9 and many patients already have evidence of 
diabetic complications and potentially modiﬁ able 
cardiovascular risk factors at the time of diagnosis.10 Early 
detection by screening is not associated with harmful 
psychological eﬀ ects11 and, therefore, diabetes meets 
many suitability criteria for screening.12 Modelling studies 
have indicated that screening would be an eﬃ  cient use of 
resources,13 but there are several critical uncertainties 
that have prevented its routine widespread imple-
mentation.14 No evidence from trials is available to show 
whether early intensive multifactorial treat ment improves 
outcomes when started between detection by screening 
and clinical diagnosis. We did the multicentre Anglo-
Danish-Dutch Study of Intensive Treatment In People 
with Screen Detected Diabetes in Primary Care 
(ADDITION-Europe) to investigate this issue.
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Methods
Design
The study design and rationale have been reported.15–18 
Brieﬂ y, ADDITION-Europe consisted of two phases: a 
screening phase and a pragmatic, cluster-randomised, 
parallel-group trial in Denmark, the Netherlands, and the 
UK (in Cambridge and Leicester). The study was approved 
by the ethics committee local to each study centre. All 
participating patients provided informed consent.
General practices in the four study areas within a 
maximum of 100 miles of the study centres were invited 
to participate according to previously reported inclu sion 
criteria.17–20 Between April, 2001, and Decem ber, 2006, 
eligible practices undertook population-based, stepwise 
screening of registered patients aged 40–69 years 
(50–69 years in the Netherlands) without known 
diabetes.17–20 Screening involved calcu lation of a risk score 
from information in general practice medical records in 
Cambridge or calcu lation of a risk score from self-
completed questionnaires in Denmark and the 
Netherlands, followed by capillary glucose testing, or by 
invitation to attend for an oral glucose tolerance test 
without previous risk assessment in Leicester.
Individuals at risk were assessed in general practice, 
and those diagnosed as having type 2 diabetes according 
to WHO criteria,21 including the requirement for 
conﬁ rmatory testing on a separate occasion, were 
included in the study. Exclusion criteria for patients were 
assessed by family physicians. They were illness with a 
life expectancy of less than 12 months or psychological or 
psychiatric disorders that might invalidate informed 
consent, or being housebound or pregnant, or lactation.
Randomisation
The practices were randomly assigned to provide 
routine diabetes care or intensive multifactorial treat-
ment in a 1:1 ratio, by statisticians in each centre, 
according to a computer-generated list, independent of 
measurement teams. 
In Denmark, randomisation included stratiﬁ cation by 
county and number of full-time family physicians. In the 
Netherlands, practices were stratiﬁ ed by single-handed 
Screening programme Intervention delivery Outcome ascertainment
Cambridge, UK Electronic medical records of patients aged 40–69 years 
searched for routinely collected information to enable 
calculation of Cambridge diabetes risk scores22
Individuals with scores ≥0·17 invited by their family 
physcian to participate in a stepwise screening 
programme, including capillary RBG, FBG, and HbA1c tests
Practice-based educational meetings held with family 
physicians and nurses to discuss treatment targets, 
algorithms, and lifestyle advice
Audit and feedback via follow-up practice-based 
meetings up to twice per year
Practice staﬀ  provided with educational materials for 
patients
Small ﬁ nancial incentives given to family physicians*
Participants tagged for mortality with the Oﬃ  ce for 
National Statistics
Sensitive electronic searches of general practice records 
undertaken between March, 2009, and February, 2010, 
in which possible events highlighted and copies made of 
medical records
Additional information obtained from hospital medical 
records and coroners’ oﬃ  ces, as required
Denmark Patients aged 40–69 years sent letters that included 
questions from the Danish Diabetes Risk Score 
Questionnaire23 and advised recipients with scores ≥5 
(high risk) to arrange an appointment with family 
physician for assessment, including RBG, FBG, and HbA1c 
tests, or patients attending family physician practice 
asked to complete risk score questionnaire and those with 
scores ≥5 underwent blood glucose tests
Small group or practice-based educational meetings 
with family physicians and nurses to discuss treatment 
targets, algorithms, and lifestyle advice
Audit and feedback included in follow-up group 
meetings up to twice per year or coordinated by post
Practice staﬀ  provided with educational materials for 
patients
Small ﬁ nancial incentives given to family physicians*
Patients sent reminders if annual assessments overdue
National patient register searched on Dec 31, 2009, for 
deaths, ICD-10 codes for cardiovascular events (I08–77), 
and surgical amputations and revascularisations. 
For possible events information obtained from hospital 
medical records and coroners’ oﬃ  ces, as required
Leicester, UK All patients aged 40–69 years invited directly for an 
OGTT in a local testing facility
Patients referred to the DESMOND structured education 
programme24
Patients oﬀ ered appointments every 2 months with a 
diabetes nurse or family physician, in a community 
clinic, for 1 year, and every 4 months thereafter
Clinic staﬀ  prompted to contact patients who missed 
appointments
Small ﬁ nancial incentives given to family physicians*
Participants tagged for mortality with the Oﬃ  ce for 
National Statistics
Sensitive electronic searches of general practice records 
undertaken between March, 2009, and February, 2010, 
in which possible events highlighted and copies made of 
medical records
Additional information obtained from hospital medical 
records and coroners’ oﬃ  ces, as required
Netherlands Patients aged 50–69 years sent letters from family 
physicians that included the Hoorn study Symptom Risk 
Questionnaire25 and advised recipients with scores ≥4 
(41 practices closest to study centre) or ≥6 (38 practices 
furthest from study centre) to arrange an appointment 
with their family physician for assessment 
Attending patients assessed with RGB, FBG, and OGTT 
(41 practices closest to study centre) or a FBG and OGTT 
(38 practices furthest from study centre)
Small group or practice-based educational meetings 
with family physicians and nurses to discuss treatment 
targets, algorithms, and lifestyle advice
Audit and feedback included in follow-up meetings up 
to twice per year or coordinated by post
Patients seen by diabetes nurses authorised to prescribe 
medication and adjust doses under supervision by 
family physicians
Patients sent reminders if annual assessments overdue
Small ﬁ nancial incentives given to family physicians*
General practice records searched manually and 
extracted endpoint and vital status information 
recorded on standard forms
For patients who had moved practice, endpoint data 
obtained by telephone interview with current family 
physician
RBG=random blood glucose. FBG=fasting blood glucose. HbA1c=glycated haemoglobin A1c. ICD-10=International Classiﬁ cation of Diseases, version ten. OGTT=oral glucose tolerance test. DESMOND=diabetes education 
and self management for ongoing and newly diagnosed programme. *Payment up to equivalent of three 10 min consultations with a family physician and three 15 min consultations wit a nurse, per patient, per year, 
for 3 years.
Table 1: Characteristics of screening programmes, intervention delivery, and outcome ascertainment, by study centre
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For the study website see 
http://www.addition.au.dk/
or group status. In the UK, randomisation included 
minimisation for the local district hospital, the number 
of patients per practice with diabetes in Cambridge, and 
for practice demographics, deprivation status, and 
prevalence of type 2 diabetes in Leicester. Patients were 
unaware of their general practice’s group assignment 
throughout the study.
Intervention
The characteristics of the intensive treatment 
intervention, which involved the addition of several 
features to existing diabetes care, have been described 
previously,15–18 and the methods used to educate and 
support staﬀ  in providing intensive treatment are 
summarised in table 1 and on the study website. Target-
driven and guideline-driven management of hyper-
glycaemia, blood pressure, and cholesterol levels by 
medical treatment and promotion of healthy lifestyles, 
based on the stepwise regimen used in the Steno-2 
study2 and other trial data obtained from people with 
type 2 diabetes,4–6,26 was added to routine care (table 2). 
The same approach was used across all centres, 
although ﬁ nal decisions about prescriptions, including 
choice of individual drugs, were made by family 
physicians and patients.
Intensive treatment was promoted to the participating 
general practices by small group or practice-based 
educational meetings attended by family physicians 
and nurses to discuss the treatment targets and 
algorithms and lifestyle advice and provide supporting 
evidence. Audit and feedback were done in follow-up 
meetings held up to twice per year or were coordinated 
by post. All participating practices received additional 
funding to support the delivery of care (up to the 
equivalent of three 10 min consultations with a family 
physician and three 15 min consultations with a nurse, 
per patient, per year for 3 years).
Family physicians were advised to consider prescribing 
angiotensin-converting-enzyme inhibitors for patients 
who had blood pressure of 120/80 mm Hg or higher, a 
cardiovascular risk factor other than diabetes, or who 
had had a previous cardiovascular event,5 and 75 mg 
aspirin daily for patients who had no speciﬁ c 
contraindications. After publication of the Heart 
Protection Study27 we altered the treatment algorithm to 
recommend pre scription of a statin to all patients with 
a cholesterol concentration of 3·5 mmol/L or higher at 
any time.
For the routine care group, family physicians were only 
provided with diagnostic test results. Patients received 
standard diabetes care, according to the recommend-
ations applicable in each centre.28–30
Outcomes
The primary endpoint was a composite of ﬁ rst 
cardiovascular event, including cardiovascular mortality, 
cardiovascular morbidity (non-fatal myocardial infarction 
and non-fatal stroke), revascularisation, and non-
traumatic amputation. The secondary outcomes were the 
individual components of the primary endpoint and all-
cause mortality. Centrally trained staﬀ  assessed patients’ 
health at baseline and after 5 years by collection of data 
on biochemical and anthropometric features and use of 
questionnaires to assess activities, including use of 
medication, according to standard operating procedures 
(see webappendix p 1). Additionally, information on 
prescribed medication, and data potentially linked to 
the endpoints were obtained from general practice 
records or national registers. All staﬀ  collecting data 
from records and undertaking health assessments were 
unaware of patients’ treatment group allocations. For 
each endpoint possibly met, the relevant clinical 
information (eg, death certiﬁ cates, post-mortem reports, 
medical records, hospital discharge summaries, 
Treatment target Treatment 
threshold
Approach at baseline if 
threshold passed
Action at review
Review 1 Review 2 Review 3
HbA1c <7·0% >6·5% Diet Value >threshold, prescribe 
metformin
Value >threshold, increase 
metformin dose or add a PGR, 
sulphonylurea, or TZD
Value >threshold, add second 
or third medication (PGR or 
sulphonurea, or TZD) and 
consider adding insulin
Blood pressure ≤135/85 mm Hg* ≥120/80 mm Hg If CVD+, prescribe an ACE 
inhibitor titrated to 
maximum dose 
Value >target, add thiazide 
diuretic or calcium-channel 
blocker
Value >target, add calcium-
channel blocker or thiazide 
diuretic 
Value >target, add β blocker or 
α blocker
Total cholesterol level 
without IHD
<5·0 mmol/L ≥3·5 mmol/L Prescribe a statin Value >target, increase statin 
dose up to maximum
Value >target, increase statin 
dose up to maximum
Value >target, consider adding 
a ﬁ brate 
Cholesterol level 
with IHD
<4·5 mmol/L ≥3·5 mmol/L Prescribe a statin Value >target, increase statin 
up to maximum dose 
Value >target, continue statin 
titration if maximum dose not 
reached
Value >target, consider adding 
a ﬁ brate
Aspirin† None None 75–80 mg daily 75–80 mg daily 75–80 mg daily 75–80 mg daily 
HbA1c=glycated haemoglobin A1c. PGR=prandial glucose regulator. TZD=thiazolidinedione. ACE=angiotensin-converting enzyme. IHD ischaemic heart disease, CVD+=cardiovascular event or presence of 
cardiovascular risk factor other than diabetes. BP=blood pressure. *≤130/80 mm Hg in Leicester. †All patients receiving antihypertensive medication and without speciﬁ c contraindications.
Table 2: Treatment recommendations and targets in the intensive treatment group
See Online for webappendix
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electrocardiographs, laboratory results, etc) were sent 
to two members of the expert committee within the 
country for independent adjudication according to an 
agreed protocol. Committee members were unaware of 
treatment allocations. Outcomes were recorded on 
standard case report forms. Committee members met 
to reach consensus over discrepancies.
The date of completion of follow-up for the primary 
endpoint was deemed to be the date of the ﬁ rst primary 
endpoint event, the 5-year assessment if no event 
occurred, or the date that the endpoint search was 
undertaken if the participant did not experience an event 
or attend follow-up.
Statistical analysis
The analysis plan was ﬁ nalised before preparation of the 
endpoint dataset, and analysis was by intention to treat. 
We summarised baseline characteristics of individuals 
and general practices within each randomised group, by 
centre, and overall. We plotted the cumulative probability 
of the primary endpoint. To assess intervention eﬀ ects we 
used Cox’s regression to estimate hazard ratios (HRs) and 
95% CI within each centre. In Leicester there were few 
participants and events and, therefore, we combined the 
endpoint data with those for Cambridge. In view of 
randomisation being at the practice level, we calculated 
robust SE that took into account the two-level structure of 
the data and any potential correlation between the 
individuals within practices. We calculated the correlation 
coeﬃ  cients within practices for the primary endpoint. 
Centre-speciﬁ c log HRs and SE were combined with a 
ﬁ xed eﬀ ects meta-analysis, and we calculated the I² statistic 
to represent the proportion of variability (in log HRs) 
between centres owing to heterogeneity. We tested the 
proportional hazards assumption by including a parameter 
for treatment by time interaction in each centre-speciﬁ c 
Cox’s regression model.
Continuous intermediate endpoints were analysed 
within each centre with normal errors regression, with 
adjustment for the endpoint baseline values; individuals 
who died or who were lost to follow-up were excluded 
from this analysis. We calculated robust SE. We 
combined the estimated diﬀ erences in mean change 
from baseline across centres with ﬁ xed eﬀ ects meta-
analysis. In the regression models, we included 
individuals with missing outcome values at baseline, 
according to the missing indicator method,31 and 
variables with a skewed distribution were log 
transformed. We estimated the eﬀ ect of the intervention 
on prescribing endpoints within each centre by use of 
logistic regression, and combined the estimated odds 
ratios across centres with ﬁ xed eﬀ ects meta-analysis. 
We undertook sensitivity analyses by excluding follow-
up clinical data obtained from general practice records, 
and did prespeciﬁ ed subgroup analyses for the primary 
endpoint by including interaction terms between 
intervention group, patient’s age, and self-reported 
history of cardiovascular disease, which were then 
pooled across centres. The cumulative incidence of the 
composite cardiovascular endpoint was calculated with 
the method for competing risks described by Gooley 
and colleagues,32 the competing events here being the 
primary endpoint and death from non-cardiovascular 
causes. For total mortality, Kaplan-Meier estimates of 
cumulative incidence were calculated. Analyses were 
done with STATA (version 11).
We calculated that a patient-level randomised trial 
would have required enrolment of 2700 individuals 
(1350 per treatment group) to detect a 30% reduction in 
the risk of the primary endpoint at a 5% signiﬁ cance 
Figure 1: Trial proﬁ le
1312 practices invited to join the study
379 practices agreed to participate
343 randomised
176 randomised to provide 
routine care (1379 patients; 
median 6 [range 1–42] per 
practice) 
167 randomised to provide 
intensive multifactorial 
treatment (1678 patients; 
median 8 [range 1–46] per 
practice) 
6 excluded
5 withdrew from
study before 
screening commenced
1 did screening but 
found no eligible 
participants 
19 excluded
11 withdrew from 
study before 
screening 
commenced
8 did screening but 
found no eligible 
participants 
157 identiﬁed patients by 
screening (1379 patients)
2 patients withdrew 
consent
157 practices included in 
primary endpoint
assessment (1377 patients)
161 identiﬁed patients by 
screening (1678 patients)
161 practices included in primary
endpoint assessment
(1678 patients)
36 excluded
19 limited health service resources 
(in Denmark)
3 allocated to pilot study 
(in Cambridge)
5 randomised to a no-screening 
control arm (in Cambridge)  
9 no search possible (in Leicester)
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Routine care Intensive treatment Change from baseline 
to follow-up 
(β/OR [95% CI])
Baseline (n=1379) Follow-up (n=1285) Baseline (n=1678) Follow up (n=1574)
Total with 
data 
available (%)
Value Total with 
data 
available (%)
Value Total with 
data 
available (%)
Value Total  with 
data 
available (%)
Value
Demographic variables
Male sex 1379 (100%) 790 (57·3%) NA NA 1678 
(100%)
981 (58·5%) NA NA NA
Mean (SD) age at 
diagnosis (years)
1379 (100%) 60·2 (6·8) NA NA 1678 
(100%)
60·3 (6·9) NA NA NA
White ethnic origin 1334 (96·7%) 1246 (93·4%) NA NA 1607 
(95·8%)
1539 (95·8%) NA NA NA
Employed 1013 (73·5%) 425 (42·0%) NA NA 1197 
(71·3%)
482 (40·3%) NA NA NA
Clinical variables
History of myocardial 
infarction
1286 (93·3%) 79 (6·1%) NA NA 1593 
(94·9%)
109 (6·8%) NA NA ··
History of stroke 1270 (92·1%) 24 (1·9%) NA NA 1558 
(92·8%)
45 (2·9%) NA NA ··
Current smoker 1347 (97·7%) 375 (27·8%) 1014 
(78·9%)
187 (18·4%) 1649 
(98·3%)
444 (26·9%) 1293 
(82·1%)
261 (20·2%) 1·06 (0·77 to 1·45)
Median (IQR) units of 
alcohol per week
1183 (85·8%) 4 (1–13) 1010 
(78·6%)
3 (0–10) 1492 
(88·9%)
4 (1–13) 1280 
(81·3%)
3 (0–10) –0·24 (–0·77 to 0·29)
Mean (SD) BMI (kg/m²) 1342 (97·3%) 31·6 (5·6) 1112 
(86·5%)
31·0 (5·6) 1615 
(96·2%)
31·6 (5·6) 1405 
(89·3%)
31·1 (5·7) 0·03 (–0·17 to 0·22)
Mean (SD) weight (kg) 1344 (97·5%) 90·3 (17·6) 1192 
(92·8%)
88·4 (17·8) 1615 
(96·2%)
90·9 (17·5) 1490 
(94·7%)
89·1 (18·2) –0·02 (–0·58 to 0·55)
Mean (SD) waist 
circumference (cm)
1346 (97·6%) 106·8 (13·5) 1064 
(82·8%)
105·3 (13·6) 1612 
(96·1%)
107·1 (13·5) 1363 
(86·6%)
105·4 (13·6) –0·30 (–1·01 to 0·42)
Median (IQR) HbA1c (%) 1298 (94·1%) 6·6 (6·1–7·3) 1226 
(95·4%)
6·5 (6·1–7·1) 1591 
(94·8%)
6·5 (6·1–7·3) 1513 
(96·1%)
6·4 (6·0–6·9) –0·08 (–0·14 to –0·02)
Mean (SD) HbA1c (%) 1298 (94·1%) 7·0 (1·5) 1226 
(95·4%)
6·7 (0·95) 1591 
(94·8%)
7·0 (1·6) 1513 
(96·1%)
6·6 (0·95) –0·08 (–0·14 to –0·02)
Mean (SD) systolic blood 
pressure (mm Hg)
1346 (97·6%) 149·8 (21·3) 1205 
(93·8%)
138·1 (17·6) 1617 
(96·4%)
148·5 (22·1) 1517 
(96·4%)
134·8 (16·8) –2·86 (–4·51 to –1·20)
Mean (SD) diastolic blood 
pressure (mm Hg)
1346 (97·6%) 86·5 (11·3) 1203 
(93·6%)
80·7 (10·8) 1618 
(96·4%)
86·1 (11·1) 1517 
(96·4%)
79·5 (10·7) –1·44 (–2·30 to –0·58)
Mean (SD) total 
cholesterol (mmol/L)
1300 (96·3%) 5·6 (1·2) 1226 
(95·4%)
4·4 (0·9) 1593 
(94·9%)
5·5 (1·1) 1523 
(96·8%)
4·2 (0·9) –0·27 (–0·34 to –0·19)
Median (IQR) HDL 
cholesterol (mmol/L)
1289 (93·5%) 1·2 (1·0–1·5) 1200 
(93·3%)
1·3 (1·1–1·6) 1568 
(93·4%)
1·2 (1·0–1·5) 1517 
(96·4%)
1·2 (1·0–1·5) 0 (–0·03 to 0·02)
Mean (SD) LDL cholesterol 
(mmol/L)
1238 (89·8%) 3·5 (1·0) 1173 
(91·3%)
2·3 (0·8) 1511 
(90·0%)
3·4 (1·0) 1477 
(93·8%)
2·1 (0·8) –0·20 (–0·26 to –0·13)
Median (IQR) triglycerides 
(mmol/L)
1295 (93·9%) 1·7 (1·2–2·4) 1213 
(94·4%)
1·6 (1·1–2·3) 1579 
(94·1%)
1·6 (1·2–2·3) 1512 
(96·1%)
1·5 (1·0–2·1) –0·05 (–0·12 to 0·01)
Mean (SD) creatinine 
(μmol/L)
1266 (91·8%) 84·9 (18·6) 1208 
(94·0%)
79·8 (29·9) 1565 
(93·3%)
83·4 (17·1) 1513 
(95·5%)
81·0 (30·5) 1·81 (0·10 to 3·53)
Self-reported drug use  
Any glucose-lowering drug 1340 (97·2%) 7 (0·5%) 1208 
(94·0%)
681 (56·4%) 1609 
(95·9%)
8 (0·5%) 1524 
(96·8%)
990 (65·0%) 1·53 (1·25 to 1·89)
Median (IQR) total 
number of glucose-
lowering drugs
1340 (97·2%) 0 (0–0) 1208 
(94·0%)
1 (0–1) 1609 
(95·9%)
0 (0–0) 1524 
(96·8%)
1 (0–1) ··
Metformin 1340 (97·2%) 5 (0·4%) 1208 
(94·0%)
583 (48·3%) 1609 
(95·9%)
6 (0·4%) 1524 
(96·8%)
835 (54·8%) ··
Sulphonylurea 1340 (97·2%) 2 (0·1%) 1208 
(94·0%)
215 (17·8%) 1609 
(95·9%)
2 (0·1%) 1524 
(96·8%)
291 (19·1%) ··
Thiazolidinedione 1340 (97·2%) 0 1208 (94·0) 50 (4·1%) 1609 
(95·9%)
0 1524 
(96·8%)
69 (4·5%) ··
Continues on next page
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level, and with 90% power. This calculation allowed for 
10% loss to follow-up and assumed an event rate in the 
routine care group of 3% per year, on the basis of the 
results of the UK Prospective Diabetes Study Group 
(UKPDS).26 We expected a minimum eﬀ ect of clustering 
within general practice, with the estimated within-cluster 
correlation coeﬃ  cient being 0·01. We assumed that the 
average number of participants per general practice 
Routine care 
(n=1377)
Intensive treatment 
(n=1678)
Hazard ratio
(95% CI)
I² (%) p for routine care vs 
intensive treatment
Primary endpoint (n [%])
Composite cardiovascular events* 117 (8·5%) 121 (7·2%) 0·83 (0·65–1·05) 0% 0·12
Secondary endpoints (n [%])
Cardiovascular death† 22 (1·6%) 26 (1·5%) 0·88 (0·51–1·51) 52% ··
Myocardial infarction† 32 (2·3%) 29 (1·7%) 0·7 (0·41–1·21) 0% ··
Stroke† 19 (1·4%) 22 (1·3%) 0·98 (0·57–1·71) 0% ··
Revascularisation† 44 (3·2%) 44 (2·6%) 0·79 (0·53–1·18) 0% ··
Amputation† 0 0 ·· ·· ··
Total mortality 92 (6·7%) 104 (6·2%) 0·91 (0·69–1·21) 55% ··
Hazard ratios were ﬁ rst estimated within each country with Cox’s regression and Huber-White adjustment of SE for clustering within practice, then combined across countries 
with ﬁ xed-eﬀ ects meta-analysis. The I² statistic estimates heterogeneity between countries. A p value was calculated for primary endpoint only. *Any of cardiovascular death, 
myocardial infarction, stroke, revascularisation, and amputation. †Component of the primary endpoint as a ﬁ rst event.
Table 4: Cardiovascular events and all-cause mortality in the two treatment groups
Routine care Intensive treatment Change from baseline 
to follow-up 
(β/OR [95% CI])
Baseline (n=1379) Follow-up (n=1285) Baseline (n=1678) Follow up (n=1574)
Total with 
data 
available (%)
Value Total with 
data 
available (%)
Value Total with 
data 
available (%)
Value Total  with 
data 
available (%)
Value
Continued from previous page
Insulin 1340 (97·2%) 0 1208 
(94·0%)
43 (3·6%) 1609 
(95·9%)
0 1524 
(96·8%)
96 (6·3%) ··
Other 1340 (97·2%) 0 1208 
(94·0%)
31 (2·6%) 1609 
(95·9%)
0 1524 
(96·8%)
81 (5·3%) ··
Any antihypertensive 
drugs
1340 (97·2%) 585 (43·7%) 1208 
(94·0%)
911 (75·4%) 1609 
(95·9%)
752 (46·7%) 1524 
(96·8%)
1274 (83·6%) 1·61 (1·27 to 2·04)
Median (IQR) total 
number of 
antihypertensive drugs
1340 (97·2%) 0 (0–1) 1208 
(94·0%)
2 (1–3) 1609 
(95·9%)
0 (0–2) 1524 
(96·8%)
2 (1–3) ··
ACE inhibitor or ARB 1340 (97·2%) 248 (18·5%) 1208 
(94·0%)
721 (59·7%) 1609 
(95·9%)
345 (21·4%) 1524 
(96·8%)
1126 (73·9%) 1·84 (1·52 to 2·22)
β-blocker 1340 (97·2%) 252 (18·8%) 1208 
(94·0%)
285 (23·6%) 1609 
(95·9%)
366 (22·7%) 1524 
(96·8%)
462 (30·3%) ··
Calcium-channel 
blocker
1340 (97·2%) 166 (12·4%) 1208 
(94·0%)
326 (27·0%) 1609 
(95·9%)
202 (12·6%) 1524 
(96·8%)
446 (29·3%) ··
Diuretic 1340 (97·2%) 330 (24·6%) 1208 
(94·0%)
529 (43·8%) 1609 
(95·9%)
415 (25·8%) 1524 
(96·8%)
767 (50·3%) ··
Other 1340 (97·2%) 23 (1·7%) 1208 
(94·0%)
49 (4·1%) 1609 
(95·9%)
32 (2·0%) 1524 
(96·8%)
70 (4·6%) ··
Any cholesterol-lowering 
drugs
1340 (97·2%) 206 (15·4%) 1208 
(94·0%)
889 (73·6%) 1609 
(95·9%)
274 (17·0%) 1524 
(96·8%)
1241 (81·4%) ··
Statins 1340 (97·2%) 200 (14·9%) 1208 
(93·9%)
864 (71·5%) 1609 
(95·9%)
271 (16·8%) 1524 
(96·8%)
1217 (79·9%) 1·46 (1·20 to 1·78)
Aspirin 1340 (97·2%) 169 (12·6%) 1208 
(93·9%)
504 (41·7%) 1609 
(95·9%)
249 (15·5%) 1524 
(96·8%)
1078 (70·7%) ··
The denominators at follow-up exclude 92 patients in the routine care group and 104 in the intensive treatment group who died between baseline and follow-up, and two others in the routine care group who 
withdrew from the study and for whom primary endpoint data were not available. The denominators used to calculate the percentages of individuals with a particular characteristic are the number of individuals 
with values for that characteristic. OR=odds ratio. NA=not applicable. BMI=body-mass index. HbA1c=glycated haemoglobin A1c. ACE-angiotensin-converting enzyme. ARB=angiotensin-receptor blocker. 
Table 3: Clinical, biochemical, and treatment characteristics of patients at baseline and mean follow-up of 5·3 years
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would be 10 and, therefore, the design eﬀ ect was 1·09. 
Thus, we inﬂ ated the estimated sample size for this 
cluster trial to 3000 patients in total.
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Of 1312 general practices invited, 379 (29%) agreed to 
participate in the study. 36 (9%) of these were excluded and 
343 (91%) were randomised to provide routine diabetes 
care (n=176) or intensive multifactorial treatment (n=167; 
ﬁ gure 1), of which 327 (routine care n=165, intensive 
treatment n=162) completed screening and 318 (routine 
care n=157, intensive treatment n=161) included eligible 
patients. Participating practices in the UK and the 
Netherlands have been described.17,18,20 The mean patient 
list size was 7378 in the routine care group and 7160 in the 
intensive treatment group. The median prevalence of 
known diabetes was 3·5%. Data for the prevalence of 
diabetes in the Denmark practices were not available. 
Screening identiﬁ ed 3233 patients with type 2 diabetes, 
of whom 3057 agreed to take part (Denmark, n=1533; 
Cambridge, UK, n=867; Netherlands, n=498; and Leicester, 
UK, n=159). The characteristics of these patients did not 
diﬀ er signiﬁ cantly from those of the 176 patients who were 
eligible but chose not to participate. Baseline demographic, 
clinical, biochemical, and treat ment characteristics of 
patients in the two treatment groups were well matched 
overall (table 3). In Denmark, however, more patients 
were identiﬁ ed in practices assigned intensive treatment 
than in those assigned routine care (910 vs 623), and more 
patients in the former group had a history of ischaemic 
heart disease (International Classiﬁ cation of Diseases 
[version 10; ICD-10] codes I20–25, 102 [11·2%] vs 53 [8·5%]) 
or other cardiac diagnosis (ICD10 codes I30–52, 76 [8·4%] 
vs 28 [4·5%]). As previously described, patients overall 
exhibited high levels of untreated cardiovascular risk 
factors at diagnosis.19
Screening programmes varied by centre (table 1). The 
median number of follow-up meetings for audit and 
feedback was four (range two to ten). Primary endpoint 
data were available for 3055 (99·9%) of 3057 participants. 
The mean follow-up period was 5·3 (SD 1·6) years, 
during which 238 ﬁ rst cardiovascular events occurred, 
with similar numbers and risk in each group (table 4). 
The cumulative probability plot for the primary endpoint 
seemed to diverge after 4 years of follow-up (ﬁ gure 2). In 
the predeﬁ ned subgroup analyses, no interactions were 
seen between the intervention and age or previous 
cardiovascular event (p>0·1). Estimated HRs, however, 
were 1·12 (95% CI 0·70–1·79) in patients younger than 
60 years and 0·70 (95% CI 0·52–0·95) in those aged 
60 years and older. HRs for individual components of the 
composite endpoint all favoured the intensive treatment 
group (table 4), although none achieved signiﬁ cance 
(ﬁ gure 2). No patient underwent amputation as a ﬁ rst 
Figure 2: Cumulative incidence and relative risk of composite cardiovascular endpoint
(A) Cumulative incidence curves by treatment group. The p value was calculated with Cox’s regression and 
ﬁ xed-eﬀ ects meta-analysis. (B) HRs of development of cardiovascular death, non-fatal myocardial infarction, 
non-fatal stroke, and revascularisation as a ﬁ rst event (secondary endpoints), and these cardiovascular events 
combined (primary endpoint), by country and overall. HR=hazard ratio. CVD=cardiovascular disease.
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event. The correlation coeﬃ  cient within clusters for the 
primary endpoint was 0·002 (Denmark: 0·014, UK 
[combined] 0·0000016, and the Netherlands 0·025), 
which suggests that the cluster design had little eﬀ ect on 
study power.
196 patients died overall (60 [30·6%] cardiovascular 
deaths, including six patients with ﬁ rst events classiﬁ ed 
as myocardial infarction, two as stroke, and four as 
revascularisation, 97 [49·5%] cancer deaths, and 
39 [19·9%] from other causes; table 4). The combined 
HR for death in the intensive treatment group compared 
with the routine care group was 0·91 (95% CI 0·69–1·21). 
Heterogeneity of results between countries was not 
signiﬁ cant (ﬁ gure 3). In the UK, signiﬁ cantly fewer 
patients died in the intensive treatment group than in 
the routine care group, but in Denmark the risk in the 
routine care group was lower, although not signiﬁ cantly 
so. All results were unchanged after sensitivity analysis 
that excluded participants in the two practices for which 
endpoint data were obtained while aware of treatment 
allocation (webappendix p 2).
Of the 2859 patients still alive at 5 years, 
2400 (84%) returned to a clinical research facility for 
follow-up health assessments. Clinical and biochemical 
outcomes could be obtained from general practice 
records for a further 328 (11·5%) participants. Compared 
with patients for whom follow-up data were available, 
the 131 with missing data were more likely to be from 
an ethnic minority group (10·2% vs 5·7%, p=0·04) and 
have higher baseline total cholesterol (5·9 mmol/L vs 
5·6 mmol/L, p=0·004) and LDL cholesterol values 
(3·7 mmol/L vs 3·4 mmol/L, p=0·009). Changes in 
clinical and biochemical values and prescribed 
medications in the two groups are shown in table 3. By 
5 years of follow-up improvements were seen for 
cardiovascular risk factors in both groups. Small but 
signiﬁ cant diﬀ erences between groups were seen in 
change from baseline for glycated haemoglobin A1c 
(HbA1c), systolic and diastolic blood pressure and total 
and LDL cholesterol, in favour of the intensive treatment 
group. Prescription of glucose-lowering, antihyper-
tensive, and lipid-lowering drugs increased in both 
groups. At follow-up more patients in the intensive 
treatment group were prescribed aspirin, angiotensin-
converting-enzyme inhibi tors or angio tensin-receptor 
blockers, glucose-lower ing drugs, antihyperten sive 
drugs, and lipid-lowering drugs than were those in the 
routine care group (table 3).
In both groups, more patients had values below target 
thresholds for HbA1c concentrations, blood pressure, 
and cholesterol concentrations at follow-up than at 
baseline (ﬁ gure 4). The proportion of patients meeting 
the targets was higher in the intensive treatment group 
than in the routine care group. The proportions of 
individuals reporting hypoglycaemia, as assessed by the 
diabetes treatment satisfaction questionnaire, did not 
diﬀ er (χ² 4·44, p=0·62).33 All results were unchanged 
after sensitivity analysis was done that excluded 
participants with follow-up clinical data obtained from 
general practice records.
Discussion
An intervention to promote target-driven, intensive 
management of patients with type 2 diabetes detected by 
screening was associated with slightly, but signiﬁ cantly, 
increased prescription of treatments and improvements 
in cardiovascular risk factors, and with a non-signiﬁ cant 
relative reduction in the incidence of cardiovascular 
events at 5 years. Diﬀ erences between study groups for 
all components of the primary endpoint favoured the 
intensive treatment group. Diﬀ erences were greatest for 
myocardial infarction and smallest for stroke.
We cannot rule out the possibility that these ﬁ ndings 
were due to chance. Rates of cardiovascular events 
seemed to diverge after 4 years of follow-up, although the 
risk of adverse outcomes, including death or self-reported 
hypoglycaemia, was not increased. The incidence of 
cardiovascular events in the routine care group (8·5%) 
was lower than expected compared with that in newly 
diagnosed patients in the UKPDS (12·1%).34 Mortality in 
this group (6·7%) was lower than that in patients with 
type 2 diabetes detected by screening in Hoorn35 (25% over 
Figure 3: Cumulative incidence and relative risk of all-cause mortality
(A) Kaplan-Meier survival estimates by treatment group. (B) HRs of all-cause mortality, by country 
and overall. HR=hazard ratio. CVD=cardiovascular disease.
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10 years) and newly diagnosed patients in a study in 
Denmark (33% over 7·4 years).36 In our study, mortality 
was similar to that reported for people of the same age 
without diabetes in the general population of Denmark 
in 1995–2006.37 This lack of diﬀ erence is likely to be due 
to the quality of care delivered to patients early in the 
course of their disease in both groups.
This trial shows that screening for type 2 diabetes and 
early intensive multifactorial treatment of the detected 
patients are feasible in general practice. In both study 
groups, cardiovascular risk factors, such as blood 
pressure and cholesterol concentrations, improved 
notably after diagnosis and glycaemia and weight did 
not increase. Absolute values for risk factors at follow-
up and changes from baseline compare favourably with 
those in other trials in which patients were recruited at 
clinical diagnosis and followed up for 6 years.34,35 
Clinically important diﬀ erences in risk factors between 
groups at 1 year,18 however, were not maintained and 
were considerably smaller than those achieved in 
similar studies.2,34
Adherence to treatment algorithms might have been 
suboptimum in this pragmatic trial. In three centres the 
screening programme used risk scores, including 
treatment for hypertension as one of the factors to predict 
the risk of type 2 diabetes, which could have limited the 
achievable diﬀ erences between groups in blood pressure. 
Furthermore, the trial was undertaken against a 
background of improvements in the delivery of diabetes 
care in general practice, such as that associated with the 
introduction of the Quality and Outcomes Framework 
for primary care in the UK,38 and evidence-based 
Panel: Research in context
Systematic review
Studies have shown cardiovascular beneﬁ ts with treatment 
to lower blood pressure and glucose and cholesterol 
concentrations in patients with type 2 diabetes mellitus.4–7 
Intensive multifactorial treatment halved risk of 
cardiovascular events and death in patients with 
longstanding diabetes and microalbuminuria in the 
STENO-2 trial.2 We searched PubMed for relevant articles by 
use of “diabetes mellitus, type 2” and “cardiovascular 
disease” as MeSH headings and the term “randomised 
controlled trial” in any heading, in combination with the 
terms “multifactorial” or “screen*”. We placed no restriction 
on language, year of publication, or study quality. We found 
no published trial evidence of the eﬀ ects of multifactorial 
treatment on cardiovascular outcomes in individuals with 
screen-detected type 2 diabetes.
Interpretation
Population screening for type 2 diabetes and subsequent 
intensive treatment is feasible. Cardiovascular risk factors 
improved in the 5 years after detection by screening, and 
rates of ﬁ rst cardiovascular events and mortality were lower 
than expected. The small diﬀ erences in prescribed 
treatment, and levels of cardiovascular risk factors, between 
groups at 5 years were associated with a non-signiﬁ cant 
17% reduction in the incidence of cardiovascular events, 
with no obvious adverse consequences. The extent to which 
the complications of diabetes can be reduced by earlier 
detection and treatment remains uncertain.
Figure 4: Proportion of patients for whom cardiovascular risk factor values were below the intensive treatment intervention target thresholds at baseline 
and after 5 years of follow-up
1 SE are shown. CVD=cardiovascular disease. HbA1c=glycated haemoglobin A1c.
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guidelines in Denmark39 and the Netherlands,40 which 
might also have lowered the achievable diﬀ erences in 
treatment between groups.
Participants were drawn from a large, representative, 
population-based sample in three diﬀ erent European 
countries. They were identiﬁ ed by a range of diﬀ erent 
screening programmes and all were diagnosed 
according to WHO criteria.21 The intensive treatment 
intervention incorporated various methods that 
encouraged changes in practitioner behaviour, and 
treatment algorithms and targets that were based on 
robust trial data.2,4,6,26 Because the intervention was 
delivered mainly via family physicians and nurses, we 
randomised general practices rather than individuals to 
minimise the risk of contamination. The analyses were 
appropriate to the cluster design. We achieved high 
participant retention and independently adjudicated 
endpoint ascertainment in both trial groups. We 
assessed clinically important outcomes with standard 
equipment and protocols by especially trained staﬀ 
members who were unaware of study group allocation. 
Patients with and without follow-up data diﬀ ered little.
The generalisability of our ﬁ ndings to other settings 
should be considered in light of the non-random 
recruitment of general practices. We did, however, cover 
a large geographical area in each country, and the 26% of 
invited practices that were randomised were nationally 
representative for key descriptive characteristics.17,18,20 
Assessment of hypoglycaemia was imprecise, as it was 
limited to one question, but we believe this factor is 
unlikely to be biased because the questionnaire was 
administered in the same way to participants in the two 
study groups by staﬀ  unaware of study group allocations. 
We feel that the size of the study means that even with a 
potentially imprecise instrument the power was suﬃ  cient 
to quantify the eﬀ ects of the intervention on the frequency 
of hypoglycaemic events. In two centres (Denmark and 
the Netherlands), assays used to assess biochemical 
factors diﬀ ered slightly between baseline and follow-up, 
but not between groups (webappendix p 1). By necessity 
cluster randomisation was done before screening and 
recruitment of patients, a design feature that can 
introduce diﬀ erences between groups in relation to 
participant characteristics. Overall, patients in the two 
study groups were well matched, although the 
intervention could have inﬂ uenced the number and type 
of patients recruited to the intensive treatment group. 
This eﬀ ect might have been particularly relevant in 
Denmark, where staﬀ  in the intensive treatment group 
might have been especially alert to the potential beneﬁ ts 
of early detection and treatment and, therefore, have 
been more active testing in individuals at high 
cardiovascular risk, which could have led to the observed 
diﬀ erences in baseline characteristics between study 
groups in this centre. These diﬀ erences between groups 
might have lessened the apparent eﬀ ects of the 
intervention and, therefore, could explain, at least partly, 
diﬀ erences between centres, which seemed to be present 
but were not necessarily signiﬁ cant owing to the limited 
power of heterogeneity test.
Methods of screening, outcome assessment, and 
laboratory testing were standard across patient groups 
within centres but did diﬀ er between centres. These 
diﬀ erences might have contributed to heterogeneity, 
even though interlaboratory validation suggested that 
methods were consistent between centres and all 
potential primary endpoints were adjudicated in the 
same way. Other sources of heterogeneity include the 
characteristics of patients, which varied by centre, 
presumably because of diﬀ erences in the screening 
programmes and underlying populations, the delivery 
of the intensive treatment intervention (table 1), and 
other unmeasured factors.
The lower-than-expected event rate suggests that 5 years 
of follow-up is insuﬃ  cient, and the apparent divergence 
from 4 years onwards suggests that further follow-up is 
justiﬁ ed to test whether early intensive multifactorial 
treatment reduces cardiovascular risk in the long term, 
as seen in the UKPDS.8 Finally, the complex nature of the 
intensive treatment intervention and the pragmatic 
design of the trial make it diﬃ  cult to say whether any 
components are individually associated with a reduction 
in cardiovascular risk.
The observed absolute and relative risks for 
cardiovascular events and mortality among participants 
with a mean HbA1c concentration of around 6·5% 5 years 
after diagnosis, should allay concerns about early 
intensive treatment of hyperglycaemia.
We saw no interaction between intensive treatment 
and age or history of cardiovascular events, although 
beneﬁ ts associated with this intervention seemed to be 
greatest in patients aged 60 years or older at diagnosis. 
Multifactorial treatment of screen-detected patients in 
both study groups was associated with improvements in 
cardiovascular risk factors and lower than expected rates 
of cardiovascular events and mortality. The small 
diﬀ erences in treatment between groups at 5 years were 
associated with a non-signiﬁ cant 17% reduction in the 
incidence of cardiovascular events, with no obvious 
adverse consequences. We are undertaking analyses of 
trial data on microvascular endpoints, quality of life, 
functional status, and health service costs. Although 
there is no evidence of harm associated with screening11 
and intensive therapy,41 the extent to which the 
complications of diabetes can be reduced by earlier 
detection and treatment remains uncertain (panel).
When compared with routine care, an intervention to 
promote target-driven, intensive management of 
patients with type 2 diabetes detected by screening was 
associated with small increases in the prescription of 
drugs and improvements in cardiovascular risk factors, 
but was not associated with signiﬁ cant reductions in 
the incidence of cardiovascular events or death over 
5 years.
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